Market capitalization | $252.78m |
Enterprise Value | $-188.83m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.62 |
P/B ratio (TTM) P/B ratio | 0.55 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-304.86m |
Free Cash Flow (TTM) Free Cash Flow | $-305.17m |
Cash position | $447.88m |
As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.
2 Analysts have issued a ACELYRIN forecast:
2 Analysts have issued a ACELYRIN forecast:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.42 -0.42 |
223%
223%
|
|
EBITDA | -304 -304 |
4%
4%
|
EBIT (Operating Income) EBIT | -305 -305 |
4%
4%
|
Net Profit | -248 -248 |
35%
35%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.
Head office | United States |
CEO | Mina Kim |
Employees | 83 |
Founded | 2020 |
Website | www.acelyrin.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.